MedTrace Logo

Treating Lid Wiper Epitheliopathy

NCT06671041 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2025-02-25

No results posted yet for this study

Summary

Lid wiper epitheliopathy (LWE) is a relatively new entry into the abundance of clinical ocular surface health signs. LWE was first reported in 2002 as a potential cause for dry eye disease (DED) (Korb et al., 2002). This clinical sign is visualised by everting the eyelid after a dye has been applied and observing the palpebral conjunctiva proximal to the eyelashes

Conditions

  • Dry Eye
  • Visual Acuity

Interventions

DRUG

Preservative Free eye drop

Participants were required to use a lubricating eye drop

Sponsors & Collaborators

  • Alcon Research

    collaborator INDUSTRY

  • Southern College of Optometry

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-27
Primary Completion
2024-08-14
Completion
2024-08-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06671041 on ClinicalTrials.gov